
Delcath Systems (DCTH) Stock Forecast & Price Target
Delcath Systems (DCTH) Analyst Ratings
Bulls say
Delcath Systems Inc has demonstrated significant growth potential, with Hepzato procedure volume increasing by 140% in 2025, underscoring heightened physician utilization and commercial adoption of its Melphalan Hydrochloride for Injection and Delcath Hepatic Delivery System. The company's liquidity position is strong, with a year-end cash balance of $91.0 million, reflecting improved operational efficiency and the financial flexibility to support its expansion initiatives. Expectations for continued salesforce growth and favorable clinical data, particularly from the CHOPIN trial, suggest a positive trajectory for referrals and treatment adoption, positioning Delcath favorably for sustained market presence and revenue growth in 2026 and beyond.
Bears say
Delcath Systems Inc. has revised its full-year revenue expectations downward to $83M-$85M, reflecting a significant decrease from prior projections of $93M-$96M, primarily due to a slowdown in new site activations and a dramatic drop in new patient starts attributed to summer seasonality and competitive clinical trials. Additionally, the company is facing challenges such as a decline in average revenue per kit related to Medicaid National Drug Rebate Agreement discounts, which have resulted in expected discounts of approximately 23% for about half of its patients. Furthermore, Delcath's ongoing cash flow negativity raises concerns regarding its ability to achieve projected revenues, contributing to a fundamentally negative outlook for its stock.
This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.
Delcath Systems (DCTH) Analyst Forecast & Price Prediction
Start investing in Delcath Systems (DCTH)
Order type
Buy in
Order amount
Est. shares
0 shares